J. Kellogg Parsons, MD, MHS, FACS

J. Kellogg Parsons, MD, MHS, FACS

San Diego, California

UC San Diego Health System

J. Kellogg Parsons, MD, MHS, is a board-certified urologist who specializes in diagnosing and treating prostate cancer. He is a Professor of Urology at the University of California, San Diego. He also directs clinical trials for the Department of Urology at UC San Diego Health’s Moores Cancer Center. Dr. Parsons is an expert in nerve-sparing robotic surgery, cryosurgery, and MRI of the prostate, and is internationally recognized for his work in prostate disease. He has repeatedly been named a top doctor in San Diego Magazine’s “Physicians of Exceptional Excellence” annual survey, performed in collaboration with the San Diego County Medical Society. He has also been recognized as one of America’s Best Doctors®. He has published over 130 scientific research articles, edited four medical textbooks, received multiple research grants, and serves as an editor on three scientific journals. He has won numerous awards for his scientific research, lectures extensively across the US and in Europe and Asia, and serves on several national committees. Dr. Parsons completed his residency and fellowship training at John Hopkins School of Medicine in Baltimore. He earned his medical degree from the University of Pennsylvania School of Medicine in Philadelphia and holds a Master of Health Science in Clinical Investigation degree from Johns Hopkins Bloomberg School of Public Health. Dr. Parsons is also the award-winning author of the novels Doing Harm and Under the Knife. He is currently at work on his third book.


Talks by J. Kellogg Parsons, MD, MHS, FACS

Men with High-Risk Prostate Cancer Should Not Undergo Neoadjuvant Therapy Prior to Surgery

J. Kellogg Parsons MD, MHS, FACS, Professor of Urology at the University of California, San Diego, explains why neoadjuvant therapy prior to surgery may not be the best option for prostate cancer patients. He reviews findings from definitive randomized clinical trials that show ADT does not improve survival, and addresses common side effects, such as cognitive impairment and loss of testosterone function. Dr. Parsons then explains AUA Clinical Guidelines published in alignment with SUO and ASTRO that strongly recommend against routine neoadjuvant therapy prior to surgery. Lastly, he gives examples of when physicians can consider the option despite such caveats.

Read More

Prostate Cancer Screening & Genetic Testing: The NCCN Perspective

J. Kellogg Parsons, MD, MHS, discusses the rationale behind the National Comprehensive Cancer Network (NCCN) guidelines on prostate cancer screening and how they fit in with currently available genetic testing. He describes the multi-disciplinary makeup of the NCCN, details considerations that led to their recommendations on when men should be screened and in which circumstances, and outlines opportunities to improve the guidelines through standardization, coordination with other organizations, and improved treatment algorithms.

Read More

Diet and Prostate Cancer- Now What?

J. Kellogg Parsons, MD, MHS, FACS, reviews the Men’s Eating and Living (MEAL) study, a randomized, phase III clinical trial testing diet intervention in prostate cancer patients under active surveillance. He describes the trial methodology and design, as well as clinical progression and quality of life outcomes.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -